Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
2.

Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms.

Neviani P, Wise PM, Murtadha M, Liu CW, Wu CH, Jong AY, Seeger RC, Fabbri M.

Cancer Res. 2019 Mar 15;79(6):1151-1164. doi: 10.1158/0008-5472.CAN-18-0779. Epub 2018 Dec 12.

PMID:
30541743
3.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2018 Jan 8;9(1):160. doi: 10.1038/s41467-017-02485-1.

4.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2017 Nov 27;8(1):1801. doi: 10.1038/s41467-017-01562-9. Erratum in: Nat Commun. 2018 Jan 8;9(1):160.

5.

Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.

Montanari S, Bartolini M, Neviani P, Belluti F, Gobbi S, Pruccoli L, Tarozzi A, Falchi F, Andrisano V, Miszta P, Cavalli A, Filipek S, Bisi A, Rampa A.

ChemMedChem. 2016 Jun 20;11(12):1296-308. doi: 10.1002/cmdc.201500392. Epub 2015 Oct 28.

PMID:
26507467
6.

Exosomic microRNAs in the Tumor Microenvironment.

Neviani P, Fabbri M.

Front Med (Lausanne). 2015 Jul 22;2:47. doi: 10.3389/fmed.2015.00047. eCollection 2015. Review.

7.

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.

Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G.

Leukemia. 2015 Nov;29(11):2143-53. doi: 10.1038/leu.2015.139. Epub 2015 Jun 9.

8.

Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M.

J Natl Cancer Inst. 2015 May 13;107(7). pii: djv135. doi: 10.1093/jnci/djv135. Print 2015 Jul.

9.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106. Epub 2015 May 14.

10.

Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies.

Milelli A, Fimognari C, Ticchi N, Neviani P, Minarini A, Tumiatti V.

Mini Rev Med Chem. 2014;14(12):963-77. Review.

PMID:
25373847
11.

SETting OP449 into the PP2A-activating drug family.

Neviani P, Perrotti D.

Clin Cancer Res. 2014 Apr 15;20(8):2026-8. doi: 10.1158/1078-0432.CCR-14-0166. Epub 2014 Mar 14.

12.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr;124(4):1512-24. doi: 10.1172/JCI70921. Epub 2014 Mar 3.

13.

Genetic events other than BCR-ABL1.

Neviani P.

Curr Hematol Malig Rep. 2014 Mar;9(1):24-32. doi: 10.1007/s11899-013-0194-x. Review.

PMID:
24407376
14.

Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.

Parise A, Milelli A, Tumiatti V, Minarini A, Neviani P, Zuccari G.

Drug Deliv. 2015;22(5):590-7. doi: 10.3109/10717544.2013.861042. Epub 2013 Nov 29.

PMID:
24286206
15.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

16.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

17.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D.

Blood. 2013 Sep 12;122(11):1923-34. doi: 10.1182/blood-2013-03-492181. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

18.

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D.

Leukemia. 2013 Oct;27(10):1996-2005. doi: 10.1038/leu.2013.151. Epub 2013 May 14.

19.

Protein phosphatase 2A: a target for anticancer therapy.

Perrotti D, Neviani P.

Lancet Oncol. 2013 May;14(6):e229-38. doi: 10.1016/S1470-2045(12)70558-2. Review.

20.

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia.

Perrotti D, Neviani P.

Cell Cycle. 2012 Dec 1;11(23):4300-1. doi: 10.4161/cc.22808. Epub 2012 Nov 16. No abstract available.

21.

Hierarchical formation of fibrillar and lamellar self-assemblies from guanosine-based motifs.

Neviani P, Sarazin D, Schmutz M, Blanck C, Giuseppone N, Spada GP.

J Nucleic Acids. 2010 Jul 13;2010. pii: 938536. doi: 10.4061/2010/938536.

22.

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J.

Cancer Cell. 2010 Jul 13;18(1):74-87. doi: 10.1016/j.ccr.2010.04.025.

23.

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM.

Cancer Res. 2010 Jul 1;70(13):5438-47. doi: 10.1158/0008-5472.CAN-09-2544. Epub 2010 Jun 15.

24.

Triggering of guanosine self-assembly by light.

Lena S, Neviani P, Masiero S, Pieraccini S, Spada GP.

Angew Chem Int Ed Engl. 2010 May 10;49(21):3657-60. doi: 10.1002/anie.201000805. No abstract available.

PMID:
20391448
25.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D.

Cell. 2010 Mar 5;140(5):652-65. doi: 10.1016/j.cell.2010.01.007.

26.

Self-assembled hexadecanitroxide.

Neviani P, Mileo E, Masiero S, Pieraccini S, Lucarini M, Spada GP.

Org Lett. 2009 Jul 16;11(14):3004-7. doi: 10.1021/ol901028h.

PMID:
19537766
27.

Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice.

Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM.

Blood. 2009 Aug 13;114(7):1374-82. doi: 10.1182/blood-2009-05-220814. Epub 2009 Jun 11.

28.

Modulation of DNA methylation by a sesquiterpene lactone parthenolide.

Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, Aimiuwu J, Pang J, Bhasin D, Neviani P, Fuchs JR, Plass C, Li PK, Li C, Huang TH, Wu LC, Rush L, Wang H, Perrotti D, Marcucci G, Chan KK.

J Pharmacol Exp Ther. 2009 May;329(2):505-14. doi: 10.1124/jpet.108.147934. Epub 2009 Feb 6.

29.

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.

Perrotti D, Neviani P.

Cancer Metastasis Rev. 2008 Jun;27(2):159-68. doi: 10.1007/s10555-008-9119-x. Review.

PMID:
18213449
30.

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA.

Cancer Cell. 2007 Nov;12(5):467-78.

31.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D.

Blood. 2008 Jan 15;111(2):816-28. Epub 2007 Oct 9.

32.

The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.

Trotta R, Ciarlariello D, Dal Col J, Allard J 2nd, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA.

J Exp Med. 2007 Oct 1;204(10):2397-405. Epub 2007 Sep 17.

33.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.

J Clin Invest. 2007 Sep;117(9):2408-21.

34.

High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D.

Blood. 2007 Aug 1;110(3):994-1003. Epub 2007 May 2.

35.

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.

Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G.

J Pharmacol Exp Ther. 2007 Jun;321(3):953-60. Epub 2007 Mar 26.

PMID:
17389244
36.

From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.

Perrotti D, Neviani P.

Clin Cancer Res. 2007 Mar 15;13(6):1638-42. Review.

37.

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.

Perrotti D, Neviani P.

Br J Cancer. 2006 Oct 9;95(7):775-81. Epub 2006 Sep 5. Review.

38.

Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.

Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B.

Blood. 2006 May 15;107(10):4080-9. Epub 2006 Jan 17.

39.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D.

Blood. 2006 Mar 15;107(6):2507-16. Epub 2005 Nov 17.

40.

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D.

Cancer Cell. 2005 Nov;8(5):355-68.

41.

BCR/ABL, mRNA translation and apoptosis.

Perrotti D, Turturro F, Neviani P.

Cell Death Differ. 2005 Jun;12(6):534-40. No abstract available.

Supplemental Content

Loading ...
Support Center